Korean J Urol.  2004 Aug;45(8):772-776.

Pre-treatment Prognostic Factors that Can Predict the Recurrence of Lower Urinary Tract Symptoms after the Treatment of Adrenergic Alpha-Antagonists in the Management of Benign Prostatic Hyperplasia

• Park JM
• Chang SG

Abstract

Purpose
The aim of this study was to conduct research on the pre- treatment prognostic factors that may influence the continuation or cessation of adrenergic alpha-antagonist (alpha-blocker) in benign prostatic hyperplasic (BPH) patients.
Materials and Methods
56 patients who were responsive to alpha-blocker, and returned for follow-up for more than 5 months, were evaluated. The patients in whom the therapeutic effect persisted for more than 8 and for less than 4 weeks after cessation of alpha-blocker were designated as groups 1 (29 patients) and 2 (27 patients), respectively. An evaluation between the groups, based on age, prostate specific antigen (PSA), total prostate volume (TPV), transition zone volume (TZV), transition zone index (TZI), International Prostate Symptom Score (I-PSS), quality of life (QoL index), peak flow rate (Qmax), residual urine, and the duration of treatment, was conduct. All parameters were initially checked before medication.
Results
This study showed that younger age, lower PSA level, smaller volume of residual urine and higher Qmax were useful indicators on the persistency of the therapeutic effect. However, TPV, TZV, TZI, I-PSS, QoL index and the duration of treatment did not affect the outcome.
Conclusions
It was concluded that age, PSA, Qmax and residual urine measured before medication were useful pre-treatment prognostic factors in the prediction of the persistency of the therapeutic effect after cessation of alpha-blockers.

Keyword

Adrenergic alpha-antagonists; Prostatic hyperplasia; Prognosis

MeSH Terms

Adrenergic alpha-Antagonists*
Follow-Up Studies
Humans
Lower Urinary Tract Symptoms*
Prognosis
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia*
Quality of Life
Recurrence*
Adrenergic alpha-Antagonists
Prostate-Specific Antigen